Blood cholesterol was 20–30% lower in the Fc-GDF15–treated obese ZSF1 rats (vs vehicle-treated animals) from week 1 to week 12 of the treatment (by two-way ANOVA: for fixed effects of treatment, p = 0.0177; for fixed effects of time, p = 0.0130; and for fixed effects of time x treatment, p = 0.017); however, this decrease did not achieve significance between the two groups at any tested time point of the study ( Fig 6E ).
← all excerpts
The evolving systemic biomarker milieu in obese ZSF1 rat model of human cardiometabolic syndrome: Characterization of the model and cardioprotective effect of GDF15.
1
—
—